Previous close | 2.5186 |
Open | 0.0000 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's range | 0.0000 - 0.0000 |
52-week range | |
Volume | |
Avg. volume | 12,412 |
Market cap | 1.884M |
Beta (5Y monthly) | 1.71 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.2930 |
Earnings date | 07 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
With the business potentially at an important milestone, we thought we'd take a closer look at Heron Therapeutics...
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webcast on Tuesday, May 7, 2024, at 8:30 a.m. ET to report first quarter 2024 financial results and discuss recent business highlights.